miR-551b and SEMA3D as Potential Therapeutic Targets in Papillary Thyroid Cancer

Xiaoli Zhang, Ph.D.¹, Sissy Jhiang, PhD², Soledad Fernandez, PhD ¹, Kevin Coombes, PhD¹
¹Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University
²Department of Physiology and Cell Biology, The Ohio State University

Abstract

Objectives: We aim to identify microRNAs and mRNAs differentially expressed in papillary thyroid cancer that correlate with clinical characteristics of the disease.

Methods: Level 3 miR-Seq data and mRNA-Seq data of thyroid cancer from The Cancer Genome Atlas (TCGA) were used for analysis. The expression level of microRNAs and mRNAs between normal and primary tumor samples were compared. The correlation between differentially expressed microRNAs/mRNAs and patients’ clinical characteristics, including tumor size (T1/T2 vs. T3/T4), lymph node status, metastatic status, extrathyroidal extension (ETE), BRAF mutation, and AJCC tumor stage (T/II vs. TIII/IV) were tested.

Results: 65 miRs and 2483 mRNAs were differentially expressed in papillary thyroid carcinoma primary tumors compared to adjacent normal tissues with more than 2-fold change. Many differentially expressed miRs were significantly correlated with BRAFV600E mutation, lymph node involvement, ETE, tumor stage, tumor size, but not with tumor metastatic status. The miR-551b was the second upregulated miRs in primary tumor compared to normal tissues (7.6 fold, p<0.0001), and was further increased in tumors from patients with lymph node metastasis or BRAF mutation. Among differentially expressed mRNAs, SEMA3D expression was significantly decreased (31.7 fold, p<0.0001) in PTC, and was further decreased in tumors from patients with lymph node metastasis, tumor stage III/IV, ETE, or BRAF mutation. SEMA3D shows significant negative correlation with miR-551b in PTC patients (r=-0.66 and p<0.0001), and miRDB predicts SEMA3D as a target of miR-551b. Both miR-551b and SEMA3D may play a critical role in thyroid cancer tumorigenesis and/or progression.

Conclusions: Deregulated miR-551b and SEMA3D may play a critical role in tumorigenesis and/or progression and they may serve as potential therapeutic targets in PTC.

MiRs associated with patient clinical characteristics

• The expression of the upregulated miRs, including miR-551b, -31, -221, -222, -375, -146b, -21, -508, are further increased; and the downregulated miRs, including miR-139, -20b, -138-1, -7-3, -1179, -7-2, -345, -152, -204, are further decreased in tumors with BRAFV600E mutation (P<0.0001 for BRAF association test).
• miR-1247, miR-127, miR-134, and miR-379 are significantly downregulated in primary tumors, but their expression was significantly increased in tumors with BRAFV600E mutation (P<0.0001 for BRAF association test).
• Most of the miRs significantly associated with BRAFV600E mutation are also associated with lymph node involvement, tumor stage III/IV, tumor size 3/4, or ETE.
• None of the differentially expressed miRs are associated with metastatic status.

MiR-551b associated with BRAFV600E mutation and lymph node involvement

miR-551b is further increased in tumors from patients with BRAFV600E mutation or lymph node involvement.

SEMA3D associated with miR-551b, BRAFV600E mutation, tumor stage (III/IV), ETE, and lymph node involvement

• SEMA3D is negatively correlated with miR-551b and is a predicted target of miR-551b.
• SEMA3D was significantly downregulated in PTC, and was further decreased in tumors from patients with lymph node involvement, BRAFV600E mutation, tumor stage III/IV, or ETE.

Conclusion

• miR-551b is associated with BRAFV600E mutation and lymph node involvement.
• SEMA3D, a predicted target of miR-551b, is associated with BRAFV600E mutation, ETE, lymph node involvement, and tumor stage III/IV.
• Therefore, miR-551b and SEMA3D axis may play a critical role in thyroid cancer tumorigenesis and/or progression.

Reference